Literature DB >> 16236821

Immunoblotting PKC-delta: a cautionary note from the bench.

Vitalyi O Rybin1, Susan F Steinberg.   

Abstract

Antibodies that specifically recognize signaling proteins (or individual phosphorylation events at specific residues in proteins of interest) have become important tools in the study of signaling pathways. However, the recognition properties of many commercially available antibodies have not been fully characterized. In the course of studies exploring PKC-delta phosphorylation mechanisms in cardiomyocytes, we have demonstrated that a BD Transduction Laboratories anti-PKC-delta MAb (generally viewed as an anti-PKC-delta protein antibody) recognizes PKC-delta in resting, but not in PMA-treated, cardiomyocytes. The observations that PKC-delta immunoreactivity is preserved when cultures are treated with PMA in the presence of a the PKC inhibitor GF-109203X and that PKC-delta immunoreactivity is restored by in vitro acid phosphatase treatment indicate that the epitope recognized by the BD Transduction Laboratories anti-PKC-delta MAb is masked by phosphorylation. The BD Transduction Laboratories MAb is poorly suited for studies that compare PKC-delta expression in resting and agonist-activated samples (or in studies of the relationship between PKC-delta phosphorylation and PKC-delta downregulation) because it artifactually displays PKC-delta phosphorylation as a decline in total PKC-delta protein. Other studies have shown that two anti-PKC-delta-pY(311) antibodies (manufactured by Cell Signaling Technology, Beverly, MA, and BioSource International, Camarillo, CA, respectively) specifically recognize stimulus-induced changes in PKC-delta-Y(311) phosphorylation on the endogenous PKC-delta enzyme, but the Cell Signaling Technology anti-PKC-delta-pY(311) antibody provides a better measure of Y(311) phosphorylation in overexpressed PKC-delta. Collectively, these studies have identified features of anti-PKC-delta antibodies that affect the interpretation of immunoblot analysis experiments. These findings related to PKC-delta may be symptomatic of a more pervasive feature of immunoblot analysis studies of phosphoproteins in general.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236821     DOI: 10.1152/ajpcell.00395.2005

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  6 in total

Review 1.  Structural basis of protein kinase C isoform function.

Authors:  Susan F Steinberg
Journal:  Physiol Rev       Date:  2008-10       Impact factor: 37.312

2.  Regulation of protein kinase C delta downregulation by protein kinase C epsilon and mammalian target of rapamycin complex 2.

Authors:  Alakananda Basu; Savitha Sridharan; Shalini Persaud
Journal:  Cell Signal       Date:  2009-07-23       Impact factor: 4.315

3.  No specific subcellular localization of protein kinase C is required for cytotoxic T cell granule exocytosis.

Authors:  Arun T Pores-Fernando; Michelle Y D Ranaghan; Adam Zweifach
Journal:  J Biol Chem       Date:  2009-07-10       Impact factor: 5.157

4.  Coincident regulation of PKCdelta in human platelets by phosphorylation of Tyr311 and Tyr565 and phospholipase C signalling.

Authors:  Kellie J Hall; Matthew L Jones; Alastair W Poole
Journal:  Biochem J       Date:  2007-09-15       Impact factor: 3.857

5.  Multiple PKCdelta tyrosine residues are required for PKCdelta-dependent activation of involucrin expression--a key role of PKCdelta-Y311.

Authors:  Ling Zhu; Chaya Brodie; Sivaprakasam Balasubramanian; Richard L Eckert
Journal:  J Invest Dermatol       Date:  2007-10-18       Impact factor: 8.551

6.  The tumor promoter-activated protein kinase Cs are a system for regulating filopodia.

Authors:  Carol A Heckman; Pratima Pandey; Marilyn L Cayer; Tania Biswas; Zhong-Yin Zhang; Nancy S Boudreau
Journal:  Cytoskeleton (Hoboken)       Date:  2017-05-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.